Sitagliptin + Placebo

Phase 1Completed

0 views this week 0 watching💤 Quiet

Interest: 29/100

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Gastroparesis

Conditions

Gastroparesis, Diabetes Mellitus

Trial Timeline

Jul 1, 2007 → Dec 1, 2011

NCT ID

NCT00501657

About Sitagliptin + Placebo

Sitagliptin + Placebo is a phase 1 stage product being developed by Merck for Gastroparesis. The current trial status is completed. This product is registered under clinical trial identifier NCT00501657. Target conditions include Gastroparesis, Diabetes Mellitus.

What happened to similar drugs?

6 of 8 similar drugs in Gastroparesis were approved

Approved (6) Terminated (4) Active (2)

✅tadalafilEli LillyApproved

✅Mosapride + domperidoneSumitomo PharmaApproved

✅Cisapride + PlaceboJohnson & JohnsonApproved

✅TegaserodNovartisApproved

✅Immediate-release omeprazole + Delayed-release omeprazoleBausch HealthApproved

🔄TradipitantVanda PharmaceuticalsPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (13)

NCT ID	Phase	Status	Start	Completion	Indication
NCT02536248	Phase 3	Completed	Aug 1, 2015	Oct 31, 2017	Type 2 Diabetes Mellitus
NCT02256189	Approved	Completed	Apr 1, 2015	Jun 1, 2017	Type 2 Diabetes
NCT02294084	Approved	Completed	Mar 1, 2014	Dec 1, 2016	Neoplasms, Adipose Tissue
NCT02015910	Approved	Terminated	Jan 1, 2014	Jan 1, 2015	Type II Diabetes
NCT01928199	Approved	Completed	Sep 1, 2013	Oct 1, 2020	Posttransplant Diabetes Mellitus
NCT01859793	Approved	Completed	Jun 1, 2013	Jul 1, 2016	Diabetes
NCT01600703	Phase 2/3	Completed	Jul 1, 2012	Aug 1, 2013	Hyperlipidemia
NCT01334229	Phase 3	Completed	Apr 1, 2011	Dec 1, 2013	Type 2 Diabetes Mellitus
NCT01272583	Pre-clinical	Completed	Mar 1, 2011	Oct 1, 2012	Type 1 Diabetes
NCT00790205	Phase 3	Completed	Dec 10, 2008	Mar 30, 2015	Type 2 Diabetes Mellitus
NCT00732121	Approved	UNKNOWN	Aug 1, 2008	Aug 1, 2010	Type 2 Diabetes
NCT00660075	Phase 3	Completed	Feb 1, 2008	Apr 1, 2009	Diabetes Mellitus
NCT00501657	Phase 1	Completed	Jul 1, 2007	Dec 1, 2011	Gastroparesis

Competing Products

19 competing products in Gastroparesis

See all competitors

Product	Company	Stage	Hype Score
tadalafil + tadalafil + placebo	Eli Lilly	Phase 2	35
Granisetron	Kyowa Kirin	Phase 2	27
tadalafil	Eli Lilly	Approved	35
Mosapride + domperidone	Sumitomo Pharma	Approved	39
Cisapride + Placebo	Johnson & Johnson	Approved	35
Cisapride + Placebo	Johnson & Johnson	Approved	35
Naloxegol 25 MG Oral Tablet [Movantik] + Placebo Oral Tablet	AstraZeneca	Phase 2	27
Tegaserod	Novartis	Approved	35
Reglan ODT	UCB	Pre-clinical	26
Hemin + Albumin	Recordati	Phase 2	32
CNSA-001 + Placebo	PTC Therapeutics	Phase 2	32
Immediate-release omeprazole + Delayed-release omeprazole	Bausch Health	Approved	37
Velusetrag + Placebo	Theravance Biopharma	Phase 2	29
velusetrag dose 1 + velusetrag dose 2 + velusetrag dose 3 + placebo	Theravance Biopharma	Phase 2	29
IW-9179 + Matching Placebo	Ironwood Pharmaceuticals	Phase 2	29
VLY-686 (Tradipitant)	Vanda Pharmaceuticals	Phase 2	25
Tradipitant	Vanda Pharmaceuticals	Phase 3	37
Tradipitant	Vanda Pharmaceuticals	Pre-clinical	20
Tradipitant + Placebo + Open Label Tradipitant	Vanda Pharmaceuticals	Phase 3	30